Could a tiny dose of lithium slow Parkinson's? early trial hints at possibility
NCT ID NCT06099886
First seen Apr 21, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This early-phase study tested a low dose of lithium aspartate (30-45 mg daily) in 15 people with early-stage Parkinson's disease. The goal was to see if lithium could change brain MRI scans and blood markers linked to the disease. The study was small and focused on safety and biological effects, not on curing Parkinson's. It is a first step toward understanding if lithium might help control the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University at Buffalo
Williamsville, New York, 14221, United States
Conditions
Explore the condition pages connected to this study.